St. Luke's Contributes to Research on Monoclonal Antibodies Made Famous by President Trump's Treatment

Patients who recovered from COVID-19 at St. Luke's University Health Network have donated their antibody-rich blood to medical science in hopes of helping to find an effective treatment or cure to the novel coronavirus that has killed nearly 200,000 Americans.  The "convalescent plasma" was separated from the survivors' blood and is being studied as part of a research project labeled AR-701, sponsored by Aridis Pharmaceuticals, a biopharmaceutical firm in San Jose, Ca., that specializes in developing innovative treatments for various infections and lung diseases.